We are live on ! Find out more
CLYM

Climb Bio
CLYM

32 hedge funds and large institutions have $311M invested in Climb Bio in 2021 Q3 according to their latest regulatory filings, with 32 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

65.08% more ownership

Funds ownership: 0% → 65.08% (+65%)

Holders
32
Holders Change
+32
Holders Change %
–
% of All Funds
0.56%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
32
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
+$272M
2
SC
Samlyn Capital
New York
+$34.7M
3
WP
Woodline Partners
California
+$8M
4
BlackRock
BlackRock
New York
+$6.86M
5
MIM
Monashee Investment Management
Massachusetts
+$6.31M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
Royal Bank of Canada
26
Royal Bank of Canada
Ontario, Canada
$14K +$16.1K +780 New
Citigroup
27
Citigroup
New York
$14K +$16.7K +806 New
Legal & General Group
28
Legal & General Group
United Kingdom
$12K +$13.6K +659 New
Bank of America
29
Bank of America
North Carolina
$11K +$12.7K +614 New
AIP
30
Ameritas Investment Partners
Nebraska
$10K +$11.2K +541 New
TRCT
31
Tower Research Capital (TRC)
New York
$9K +$10.1K +491 New
Wells Fargo
32
Wells Fargo
California
$1K +$640 +31 New
1
2

CLYM Hedge Fund Activity: Q3 2021 in Review

32 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Climb Bio (CLYM) for Q3 2021, worth a combined $311M.

Buyers outnumbered sellers: 32 funds opened new CLYM positions and 0 closed out — a net gain of 32 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was RA Capital Management, opening a new position worth an estimated $272M.

  • 32 institutional investors held Climb Bio (CLYM) as of Q3 2021, up from 0 in Q2 2021.
  • Funds reported $311M of Climb Bio stock for Q3 2021.
  • 32 funds opened new Climb Bio positions in Q3 2021 and 0 closed out, a net change of +32 holders.
  • The largest Climb Bio buyer in Q3 2021 was RA Capital Management, an estimated $272M added.

Based on aggregated 13F filings for Q3 2021.